Section Arrow
ALT.NASDAQ
- Altimmune
Quotes are at least 15-min delayed:2024/05/13 16:55 EDT
Last
 7.37
+0.15 (+2.08%)
Day High 
7.57 
Prev. Close
7.22 
1-M High
8.54 
Volume 
2.18M 
Bid
7.31
Ask
7.36
Day Low
7.115 
Open
7.32 
1-M Low
6.282 
Market Cap 
511.86M 
Currency USD 
P/E -- 
%Yield
10-SMA 7.12 
20-SMA 7.19 
50-SMA 8.63 
52-W High 14.84 
52-W Low 2.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.66/-1.57
Enterprise Value
512.04M
Balance Sheet
Book Value Per Share
2.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
426.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NVAXNovavax13.11+4.23+47.64%-- 
DNAGinkgo Bioworks Holdings0.8407+0.0798+10.49%-- 
ACIUAC Immune SA3.3+0.99+42.86%-- 
JAGXJaguar Health0.290795-0.001305-0.45%-- 
TVGNTevogen Bio Holdings1+0.0155+1.57%-- 
Quotes are at least 15-min delayed:2024/05/13 16:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.